H.U. Group Holdings,Inc. Q4 FY2025 earnings call

• Overall Consolidated Financial Performance

  • Full-year 2024 reported year-over-year growth in revenue (up 6.1 billion yen), EBITDA (up 6.6 billion yen), operating profit (up 6.7 billion yen), and net income (up 10.3 billion yen).
  • 2024 EBITDA now exceeds pre-COVID (2019) levels and reaches the performance levels seen in 2017 and 2018.
  • Operating cash flow reached 22 billion yen, also exceeding all pre-COVID (2017-2019) levels, with free cash flow increasing year-over-year driven by higher operating cash flow.
  • Net interest-bearing debt has trended downward gradually despite an increase in lease obligations.
  • A 3.07 billion yen non-operating gain was recorded from distributions from a 2017 venture fund investment, and significant reductions in equity method losses were realized following exits from underperforming international ventures.
  • Reported net income landed at 2.8 billion yen.

• Capital Allocation (2020-2024 5-Year Summary)

  • Cumulative operating cash flow of 161.9 billion yen was generated over the 5-year period, plus an additional 10 billion yen from asset sales, for a total of 171.9 billion yen allocated to investments, dividends, M&A for the IVD segment, and debt repayment.
  • Future capital allocation plans will be detailed in the upcoming mid-term management plan announcement.

• Operational Update

  • The H.U. Bioness Complex has now begun full operations. One-time transitional costs are expected only in Q1 2025, related to delayed customer billing transfers, post-launch hyper-care support, and legacy mainframe system shutdown costs; no one-time costs are expected from Q2 2025 onward.
  • The company is introducing segment-level ROIC management starting in 2025, with external disclosure of this metric.

• Shareholder Return Policy

  • The longstanding stable dividend policy is maintained, with a new progressive dividend commitment and a continued target of 6% DOE. The 2025 per-share dividend is planned at 125 yen, unchanged from the prior year.
  • A 5 billion yen share repurchase program was approved, the company's first share repurchase in 10 years, to be added as a regular flexible tool for shareholder return as the company increases return commitments in its new mid-term plan.

1. LTS (Laboratory Testing Service) Segment: Excluding COVID-19 related sales, base business revenue grew 6% year-over-year, with total test volumes increasing approximately 5%. The segment delivered increased profit, driven by gradual realization of profitability improvement initiatives, revenue growth, and lower year-over-year costs related to the H.U. Bioness Complex. Fixed cost reduction targets were not met for the full year, leaving this as an outstanding operational challenge.

2. IVD (In-Vitro Diagnostics) Segment: NEURO reagent-related sales reached 4.7 billion yen, growing 2.4x year-over-year, outperforming initial forecasts. Overall segment revenue declined year-over-year entirely due to falling COVID-19 related sales; excluding COVID-19, the base business delivered revenue growth. The segment's operating profit margin fell below the 20% target for the year, as the company is currently in an R&D intensive phase, investing 15% of segment revenue in R&D.

3. HS (Sterilization & Surgery Related) Segment: Both revenue and profit increased year-over-year, driven by solid performance of core business operations and ongoing profitability improvements.

• For full-year 2025, the company targets accelerating profit growth, with a goal of 30.5 billion yen in EBITDA and 8 billion yen in operating profit, moving close to the company's previous all-time high EBITDA excluding international testing business.
• LTS segment targets 5% total revenue growth, with 4% growth from base testing (driven by new customer acquisition and service level optimization) and 7% growth from genetic testing. The non-negotiable core priority for the segment is achieving full operating profitability in 2025, targeting a 5 billion yen year-over-year increase in operating profit. One-time H.U. Bioness Complex costs will decline year-over-year, offset by higher depreciation and running costs, leaving overall related costs roughly flat year-over-year.
• IVD segment expects solid profit growth driven by CDMO (Contract Development and Manufacturing Organization) and NEURO, with only a slight net year-over-year profit increase after accounting for continued COVID-19 sales declines and global macro headwinds. CDMO growth will accelerate as shipments to new partners (which began in H2 2024) scale up. NEURO growth will be supported by plans for stable commercial supply of the pTau217/Aβ1-42 plasma reagent pending FDA approval, plus pipeline expansion into non-Alzheimer's NEURO areas. The IVD business will continue investing ~12% of segment revenue in R&D focused on NEURO and new Lumipulse product development.
• Capital expenditure peaked in prior periods, with 2025 capex focused mostly on maintenance. Depreciation will peak in 2025 and begin declining in subsequent years.
• Full mid-term management guidance and long-term capital allocation plans will be presented at an upcoming dedicated strategy briefing.

• Full-year 2024 Q4 operating profit missed the February guidance target of 1.8 billion yen, driven by three main factors: slower-than-expected fixed cost reduction in the LTS segment, weaker-than-expected IVD base business performance plus a reclassification of some expected operating profit to non-operating income, and unplanned advisory expenses company-wide. This led to a further downward revision to full-year results, and management has committed to improving forecasting accuracy for 2025.
• LTS faces expected cost increases in 2025 from reagent and consumable price hikes driven by current market conditions.
• IVD faces headwinds from global macroeconomic uncertainty and foreign exchange volatility in 2025.
• The fixed cost reduction initiative in LTS missed targets in 2024, creating pressure to deliver on these cost cuts in 2025.

Q: Can you review why 2024 results missed the initial full-year forecast, particularly regarding LTS profitability improvement targets? / A: Management confirms that marginal profit improvement hit the planned 2024 target exactly. However, fixed cost reduction (including payroll and overhead expenses) missed goals despite multiple initiatives, which management attributes to over-optimism in the original planning. For 2025, the profit growth plan is weighted heavily toward marginal profit gains, with only modest fixed cost reduction targets built in, to reflect the 2024 outcome and ensure forecasts reflect only reliably achievable initiatives. Implementation of all 2025 plans is already underway to ensure target delivery.

Q: Given the 2025 plan relies almost entirely on LTS profit growth from sales growth and marginal profit improvement, how will benefit realization timeline break down between the first and second half of the year? / A: Sales growth will be realized evenly across the full year. Marginal profit improvements, particularly price adjustments, will be implemented mostly in the first half, with impacts starting to appear in H1. Laboratory operation efficiency improvements will be pursued across the full year with gradual benefit realization. Price adjustments are targeted for completion by the end of H1, so their full benefits will be realized in the second half of 2025.

Q: Does this mean profit generation will be heavily weighted toward the second half of 2025? / A: That is the expected profile. Q1 2025 will face 1 billion yen in one-time transitional costs for the H.U. Bioness Complex, making it the most challenging quarter of the year. Full benefit realization from all 2025 initiatives will come in the second half of the fiscal year.